Experimental gene injection aims to save sight in rare eye disease
Disease control
Completed
This early-phase trial tested a gene therapy called ZM-01 in 2 boys aged 3 to 18 with X-linked retinoschisis, a rare genetic eye condition that causes vision loss. Each boy received an injection of the therapy into one eye. The main goal was to check safety, but researchers also …
Phase: EARLY_PHASE1 • Sponsor: Zhongmou Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC